

Analytical Studies on Certain Fluoroquinolones

Thesis

Presented for the fulfillment of the degree of Ph.D.
In pharmaceutical sciences
(Pharmaceutical Analytical Chemistry)

By

Nehad Amin Abdallah Radwan

Experiments and Advanced Pharmaceutical Research
Unit (*EAPRU*)
Faculty of Pharmacy
Ain Shams University

Under the Supervision of

Prof. Dr. Amira Mabrouk El-kosasy

Professor and head of Pharmaceutical Analytical Chemistry department
Faculty of Pharmacy
Ain Shams University

Dr. Miriam Farid Ayad

Lecturer of Analytical Chemistry
Faculty of Pharmacy
Ain Shams University

**Pharmaceutical Analytical Chemistry Department
Faculty of Pharmacy – Ain Shams University
2013**

دراسة تحليلية على بعض الفلوروكينز

رسالة

مقدمة للحصول على درجة
دكتوراه الفلسفة في العلوم الصيدلانية
(الكيمياء التحليلية الصيدلانية)
من

الصيدلانية الماجستير / نهاد أمين عبد الله
وحدة التجارب و البحوث الصيدلانية المتقدمة
كلية الصيدلة
جامعة عين شمس

تحت إشراف
أ.د/ أميرة مبروك القصاص
أستاذ و رئيس قسم الكيمياء التحليلية الصيدلانية
كلية الصيدلة- جامعة عين شمس

/ ميريام فريد عياد
مدرس الكيمياء التحليلية
كلية الصيدلة- جامعة عين شمس

قسم الكيمياء التحليلية الصيدلانية
كلية الصيدلة- جامعة عين شمس

2013

Acknowledgement

Primarily, I am deeply thankful to Allah by the grace of whom, this work was possible.


*I would like to express my sincere gratitude and appreciation to Prof. Dr. **Amira Mabrouk El-Kosasy**, Professor and head of Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy, Ain Shams University, for her keen supervision, generous assistance, and unlimited support during this work,*

*My sincerest appreciation and thanks to Dr. **Miriam Farid Ayad**, Lecturer of Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, for her keen supervision, helpful suggestions and constant support she offered me.*

*I also express my gratefulness to **my husband and my sister** for their constant support and help to complete this work,*

*I wish also to express my thanks to **Younan Ayad** Researcher, Faculty of Pharmacy, Ain Shams University, for his great assistance and helpful suggestions he offered to me.*

*Lastly, I would like to thank all my colleagues especially **Heba Fathy Ibrahim** for their great support and constant help.*



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقُلْ أَعْمَلُوا فِى سَبِيلِ اللَّهِ عَمَلَكُمْ وَرَسُولُهُ وَالْمُؤْمِنُونَ وَسَتُرَدُّوكَ إِلَى
عِلْمِ الْغَيْبِ وَالشَّهَادَةِ فَيُنَبِّئُكُمْ بِمَا كُنْتُمْ تَعْمَلُونَ ﴿١٠٥﴾

التوبة: ١٠٥

صَدَقَ اللَّهُ الْعَظِيمُ

CONTENTS

List of abbreviations	XXIV
Preface	XXVII
Summary	XXIX

PART (I)

INTRODUCTION

I.1. Introduction	1
I.2. History and Development of the Quinolones	2
I.3. Structure Activity Relationship (SAR) of Fluoroquinolones	6
I.4. Mechanism of Action	11
I.5. Structure -Side Effects Relationship	13
I.6. Drug interaction	15

PART (II)

LITERATURE REVIEW

II.1. Pazufloxacin mesylate	16
II.1.1. Stability	16
II.1.2. Methods of Analysis in Literature	17
II.1.2.1 Spectrophotometric Methods	17
II.1.2.2. Spectrofluorimetric Methods	19
II.1.2.3. Electrochemical Methods	19
II.1.2.4. Chromatographic Methods	20
II.2. Gemifloxacin mesylate	23
II.2.1. Stability	24
II.2.2. Methods of Analysis in Literature	27
II.2.2.1 Spectrophotometric Methods	27
II.2.2.2. Spectrofluorimetric Methods	31
II.2.2.3. Electrochemical Method	32
II.2.2.4. Chromatographic Methods	33

PART (III)

Study of Acidic And Alkaline Degradation of Pazufloxacin And Gemifloxacin Mesylate

SECTION (A): Stability-Indicating TLC Spectrodensitometric Method for Determination of Pazufloxacin and Gemifloxacin Mesylate in Presence of Their Acidic and Alkaline Degradates.

III.A.1. Introduction	40
III.A.2.Experimental Study	40
III.A.2.1. Instrumentation	40
III.A.2.2. Materials	41
III.A.2.2.1. Pure Samples	41
III.A.2.2.2 Market Samples	42
III.A.2.2.3. Chemicals and Reagents	42
III.A.2.3. Standard Solutions	42
III.A.2.4. Preparation of Degradation Products	43
III.A.2.5. Procedure	45
III.A.2.5.1. Chromatographic Conditions	45
III.A.2.5.2. Method Validation	46
III.A.3. Results and Discussion	51

SECTION (B): Stability-Indicating High Performance Liquid Chromatographic Method for Determination of Pazufloxacin and Gemifloxacin in Presence of their Acidic and Alkaline Degradation Products

III.B.1. Introduction	73
III.B.2.Experimental Study	74
III.B.2.1. Instrumentation	74
III.B.2.2. Materials	74
III.B.2.2.1. Pure Samples	74
III.B.2.2.2 Market Samples	75
III.B.2.2.3. Chemicals and Reagents	75

III.B.2.3. Standard Solutions	75
III.B.2.4. Preparation of Degradation Products	76
III.B.2.5. Procedure	78
III.B.2.5.1. Chromatographic Conditions	78
III.B.2.5.2. Method Validation	79
III.B.3. Results and Discussion	85

SECTION (C): Separation and Structural Elucidation of Pazufloxacin and Gemifloxacin Acidic and Alkaline Degradation Products

III.C.1. Introduction	106
III.C.2. Experimental Study	107
III.C.2.1. Instrumentation	107
III.C.2.2. Materials	108
III.C.2.2.1. Pure samples	108
III.C.2.2.2. Chemicals and Reagents	108
III.C.2.3. Separation of Pazufloxacin and Gemifloxacin Acidic and Alkaline Degradation Products	109
III.C.2.3.1. Pazufloxacin and Gemifloxacin Acidic Degradation Products	109
III.C.2.3.2. Pazufloxacin and Gemifloxacin Alkaline Degradation Products	109
III.C.2.3.3 Preparation of Silica Gel Column Chromatography	110
III.C.3. Results and Discussion	112

SECTION (D): Kinetic Studies of Acid and Alkaline Promoted Degradation of Pazufloxacin and Gemifloxacin Mesylate

III.D.1. Introduction	145
III.D.2. Experimental Study	146
III.D.2.1. Instrumentation	146
III.D.2.2. Pure Samples	146
III.D.2.3. Chemicals and Reagents	146

III.D.2.4. Standard Solutions	146
III.D.2.5. Procedure	147
III.D.2.5.1. Studying the Kinetic Order of the Reaction	147
III.D.2.5.2. Studying the Effect of the Reagent Concentration on the Reaction Rate	150
III.D.2.5.3. Studying the Effect of the Temperature on the Reaction Rate	151
III.D.3. Results and Discussion	152

Part IV

Ion Selective Electrode- based Potentiometric Methods for the Determination of Pazufloxacin and Gemifloxacin in Presence of their Acidic and Alkaline Degradation Products and in Plasma

IV.1. Introduction	173
IV.2. Experimental Study	176
IV.A.2.1. Instrumentation	176
IV.A.2.2. Materials	176
IV.A.2.2.1. Pure samples	176
IV.2.2.2. Market samples	177
IV.2.2.3. Chemicals and Reagents	177
IV.2.3. Standard Solutions	179
IV.2.4. Procedures	180
IV.2.4.1. Preparation of Coated Graphite Electrodes	180
IV.2.4.3. Direct Potentiometric Determination of Pazufloxacin and Gemifloxacin in Bulk Powder	182
IV.2.4.3. Direct Potentiometric Determination of Pazufloxacin and Gemifloxacin in Their Pharmaceutical Formulations	182
IV.2.4.4. Direct Potentiometric Determination of Pazufloxacin and Gemifloxacin in Presence of their Acidic and Alkaline Degradates	184
IV.2.4.5. Direct Potentiometric Determination of Pazufloxacin and Gemifloxacin in Presence of Plasma	184

IV.2.4.6. Experimental Conditions	185
IV.3. Results and Discussion	188

Part V

Simultaneous Chromatographic Determination of each of Pazufloxacin and Gemifloxacin with Some Co-administered Drugs in Spiked Human Plasma

V.1. Introduction	220
-------------------------	-----

SECTION (A): HPLC determination of each of Pazufloxacin and Gemifloxacin with Some Co-administered Drugs in Spiked Human Plasma

V.A.1. Studied drugs	224
V.A.2. Experimental Study	227
V.A.2.1. Instrumentation	227
V.A.2.2. Materials	228
V.A.2.2.1. Pure Samples	228
V.A.2.2.2. Chemicals and Reagents	228
V.A.2.3. Standard Solutions	229
V.A.2.4. Procedure	231
V.A.2.4.1. Plasma Samples Processing	231
V.A.2.4.2. Chromatographic conditions	234
V.A.2.4.3. Method Validation	235
V.A.3. Results and Discussion	242

SECTION (B): TLC Densitometric Determination of each of Pazufloxacin and Gemifloxacin with Some Co-administered Drugs in Spiked Human Plasma

V.B.1. Studied drugs	271
V.B.2. Experimental Study	271
V.B.2.1. Instrumentation	271
V.B.2.2. Materials	272

V.B.2.2.1. Pure Samples	272
V.B.2.2.2. Chemicals and Reagents	272
V.B.2.3. Standard Solutions	272
V.B.2.4. Procedure	274
V.B.2.4.1. Plasma Samples Processing	274
V.B.2.4.2. Chromatographic conditions	277
V.B.2.4.3. Method Validation	278
V.B.3. Results and Discussion	286
References	315

LIST OF FIGURES

Figure No.		Page No.
(1)	Clinical development of quinolones	3
(2)	Structure modification of chloroquine for synthesis of fluoroquinolones.	6
(3)	SAR of fluoroquinolones.	7
(4)	Structure pharmacokinetics relationships.	8
(5)	Mechanism of action of fluoroquinolones.	12
(6)	Structure of adverse reaction relationships of fluoroquinolones.	14
(7)	Probable structures of degradates after acidic (a) and alkaline (b) degradations.	26
(8)	Degradation pathway of gemifloxacin after acidic, basic and oxidative conditions.	26
(9)	TLC plate as visualized under UV lamp at 254 nm where: a- Intact pazufloxacin mesylate b- Acidic degradation products c- Alkaline degradation products	59
(10)	TLC densitogram of pazufloxacin mesylate	60
(11)	TLC densitogram of pazufloxacin acidic degradation sample	60
(12)	TLC densitogram of pazufloxacin alkaline degradation sample	61

Figure No.		Page No.
(13)	TLC plate as visualized under UV lamp at 254 nm where: A- Intact gemifloxacin mesylate B- Acidic degradation products C- Alkaline degradation products	62
(14)	TLC densitogram of gemifloxacin mesylate	63
(15)	TLC densitogram of gemifloxacin acidic degradation sample	63
(16)	TLC densitogram of gemifloxacin alkaline degradation sample	64
(17)	TLC calibration curve correlating the peak area at 249nm to the corresponding concentration of pazufloxacin mesylate	65
(18)	TLC calibration curve correlating the peak area at 266nm to the corresponding concentration of gemifloxacin mesylate	65
(19)	HPLC chromatogram of pazufloxacin mesylate (10 µg/ml)	95
(20)	HPLC chromatogram of pazufloxacin stressed acidic degradation sample	95
(21)	HPLC chromatogram of pazufloxacin stressed alkaline degradation sample	96
(22)	HPLC chromatogram of gemifloxacin mesylate (10 µg/ml)	96

Figure No.		Page No.
(23)	HPLC chromatogram of gemifloxacin stressed acidic degradation sample	97
(24)	HPLC chromatogram of gemifloxacin stressed alkaline degradation sample	97
(25)	HPLC calibration curve correlating the peak area at 249nm to the corresponding concentration of pazufloxacin (2 – 40 µg/ml)	98
(26)	HPLC calibration curve correlating the peak area at 266nm to the corresponding concentration of gemifloxacin (2.5 – 50 µg/ml)	98
(27)	Separation procedure using silica column chromatography	112
(28)	IR, LC-MS/MS and ¹ H NMR spectra of the intact pazufloxacin mesylate	119
(29)	IR, LC-MS/MS and ¹ H NMR spectra of pazufloxacin acidic degradation product (PD1)	120
(30)	Proposed acidic degradation reaction of pazufloxacin using 1M HCl at 70 °C for 2 hrs	121
(31)	IR, LC-MS/MS and ¹ H NMR spectra of pazufloxacin alkaline degradation product (PD2)	122
(32)	IR, LC-MS/MS and ¹ H NMR spectra of pazufloxacin alkaline degradation product (PD3)	123
(33)	Proposed alkaline degradation reaction of pazufloxacin	124

Figure No.		Page No.
	using 1M NaOH at 70 °C for 2 hrs	
(34)	IR, LC-MS/MS and ¹ H NMR spectra of the intact gemifloxacin mesylate	125
(35)	IR, LC-MS/MS and ¹ H NMR spectra of gemifloxacin acidic degradation product (GD1)	126
(36)	IR, LC-MS/MS and ¹ H NMR spectra of gemifloxacin acidic degradation product (GD2)	127
(37)	IR, LC-MS/MS and ¹ H NMR spectra of gemifloxacin acidic and alkaline degradation product (GD3)	128
(38)	Proposed acidic degradation reaction of gemifloxacin using 1M HCl at 70 °C for 2 hrs	129
(39)	IR, LC-MS/MS and ¹ H NMR spectra of gemifloxacin alkaline degradation product (GD4)	130
(40)	IR, LC-MS/MS and ¹ H NMR spectra of gemifloxacin alkaline degradation product (GD5)	131
(41)	IR, LC-MS/MS and ¹ H NMR spectra of gemifloxacin alkaline degradation product (GD6)	132
(42)	Proposed acidic degradation reaction of gemifloxacin using 1M NaOH at 70 °C for 2 hrs	133
(43)	Kinetic plot of acid degradation for 30µg/ml and 40 µg/ml Pazufloxacin solutions in methanol using 1M HCl at 70°C.	158
(44)	Kinetic plot of acid degradation for 40µg/ml and	158